1982 Federal Register / Vol. 86, No. 6 / Monday, January 11, 2021 / Notices 

exposed to chemicals as mixtures. 

Assessing the safety of a mixture is a 

complex process that requires 

consideration of both the toxicity of 

each chemical component of the 

mixture and the potential for interaction 

among the components to affect toxicity 

of the overall mixture. Additionally, 

most alternative methods and 

approaches used for assessing chemical 

safety are developed and evaluated 

using single chemicals. This can result 

in lack of clarity about whether a 

method is appropriate to use for 

assessing toxicity of a particular 

mixture. 

This webinar will discuss new 

approach methodologies for assessing 

exposure to, and potential hazards 

associated with, chemical mixtures. Key 

insights and ongoing activities will be 

described in three presentations 

featuring speakers from U.S. federal 

research and regulatory agencies. The 

preliminary agenda and additional 

information about presentations will be 

posted at https://ntp.niehs.nih.gov/go/ 

commprac-2021 as available. 

Webinar and Registration: This 

webinar is open to the public with time 

scheduled for questions by participants 

following each presentation. 

Registration for the webinar is required 

and will be open from January 4, 2021, 

through 11:00 a.m. EST on January 26, 

2021. Registration is available at https:// 

ntp.niehs.nih.gov/go/commprac-2021. 

Interested individuals are encouraged to 

visit this web page to stay abreast of the 

most current webinar information. 

Registrants will receive instructions on 

how to access and participate in the 

webinar in the email confirming their 

registration. 

Background Information on ICCVAM 

and NICEATM: ICCVAM is an 

interagency committee composed of 

representatives from 17 federal 

regulatory and research agencies that 

require, use, generate, or disseminate 

toxicological and safety testing 

information. ICCVAM conducts 

technical evaluations of new, revised, 

and alternative safety testing methods 

and integrated testing strategies with 

regulatory applicability. ICCVAM also 

promotes the scientific validation and 

regulatory acceptance of testing 

methods that more accurately assess the 

safety and hazards of chemicals and 

products and replace, reduce, or refine 

(enhance animal well-being and lessen 

or avoid pain and distress) animal use. 

The ICCVAM Authorization Act of 

2000 (42 U.S.C. 285l–3) establishes 

ICCVAM as a permanent interagency 

committee of NIEHS and provides the 

authority for ICCVAM involvement in 

activities relevant to the development of 

alternative test methods. Additional 

information about ICCVAM can be 

found at https://ntp.niehs.nih.gov/go/ 

iccvam. 

NICEATM administers ICCVAM, 

provides scientific and operational 

support for ICCVAM-related activities, 

and conducts and publishes analyses 

and evaluations of data from new, 

revised, and alternative testing 

approaches. NICEATM and ICCVAM 

work collaboratively to evaluate new 

and improved testing approaches 

applicable to the needs of U.S. federal 

agencies. NICEATM and ICCVAM 

welcome the public nomination of new, 

revised, and alternative test methods 

and strategies for validation studies and 

technical evaluations. Additional 

information about NICEATM can be 

found at https://ntp.niehs.nih.gov/go/ 

niceatm. 

Dated: January 6, 2021. 

Brian R. Berridge, 

Associate Director, National Toxicology 

Program. 

[FR Doc. 2021–00227 Filed 1–8–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Improving Technologies to 

Make Large-scale High Titer Phage Preps 

(Topic 95). 

Date: February 5, 2021. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E72A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Frank S. De Silva, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E72A, Rockville, MD 

20892–9823, (240) 669–5023, fdesilva@

niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2018–1 Phase II: Improving Technologies to 

Make Large-scale High Titer Phage Preps 

(Topic 95). 

Date: February 5, 2021. 

Time: 3:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E72A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Frank S. De Silva, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E72A, Rockville, MD 

20892–9823, (240) 669–5023, fdesilva@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 5, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00222 Filed 1–8–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Amended Notice 

of Meeting 

Notice is hereby given of a change in 

the meeting of the Council of Councils, 

January 29, 2021, 10:00 a.m. to 05:00 

p.m., a virtual meeting, which was 

published in the Federal Register on 

November 25, 2020, 85 FR 75342. 

The meeting notice is amended to 

change the open session meeting end 

time as follows: The open session will 

now be held from 11:00 a.m. to 3:50 

p.m. 

Dated: January 5, 2021. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00221 Filed 1–8–21; 8:45 am] 

BILLING CODE 4140–01–P 


jbell on DSKJLSW7X2PROD with NOTICES